Burning Rock Biotech (NASDAQ:BNR) Stock Price Up 1% – Here’s What Happened

by · The Cerbat Gem

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report)’s share price was up 1% during mid-day trading on Wednesday . The stock traded as high as $16.70 and last traded at $16.8650. Approximately 2,207 shares changed hands during trading, a decline of 89% from the average daily volume of 20,119 shares. The stock had previously closed at $16.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on BNR

Burning Rock Biotech Price Performance

The company has a market cap of $177.42 million, a P/E ratio of -21.35 and a beta of 1.49. The stock has a 50-day moving average of $18.22 and a 200 day moving average of $21.46.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.The company had revenue of $18.05 million during the quarter.

Insider Activity at Burning Rock Biotech

In other Burning Rock Biotech news, Director Yusheng Han bought 314,870 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average price of $17.36 per share, for a total transaction of $5,466,143.20. Following the completion of the transaction, the director directly owned 17,672,676 shares in the company, valued at approximately $306,797,655.36. The trade was a 1.81% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 30.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Crcm LP grew its position in Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after acquiring an additional 269,851 shares during the last quarter. Renaissance Technologies LLC grew its position in Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after acquiring an additional 4,290 shares during the last quarter. Prospera Financial Services Inc grew its position in Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after acquiring an additional 6,430 shares during the last quarter. Marshall Wace LLP bought a new position in Burning Rock Biotech in the fourth quarter valued at about $220,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Burning Rock Biotech in the third quarter valued at about $26,000. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

See Also